ASH 2021 | Emerging immunotherapeutic strategies for multiple myeloma in the frontline and R/R settings
Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, gives an overview of the topics discussed at a satellite symposium on emerging treatment strategies in multiple myeloma. Experts spoke on the addition of anti-CD38 monoclonal antibodies to frontline therapy, as well as on the latest updates in BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapies, antibody-drug conjugates and bispecific antibodies in later lines of treatment. There is currently a lot of interest in investigating the efficacy of these immunotherapies in earlier lines of treatment. Data on venetoclax-based combinations for patients with t(11;14) translocation was also shared. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Disclosures
Janssen: Other: Advisory Board; Novartis: Consultancy; Oncopeptides: Consultancy, Honoraria; TeneoBio: Other: Advisory Board; Adaptive Biotechnologies: Other: Advisory Board; BMS: Other: Advisory Board; GSK: Honoraria.
